Comparison 6. Fondaparinux versus LMWH sensitivity analysis.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 total VTE	13	9709	Risk Ratio (M‐H, Random, 95% CI)	0.57 [0.43, 0.74]
2 symptomatic VTE	11	12569	Risk Ratio (M‐H, Fixed, 95% CI)	1.08 [0.69, 1.70]
3 total DVT	12	9726	Risk Ratio (M‐H, Random, 95% CI)	0.55 [0.42, 0.72]
4 proximal DVT	10	8528	Risk Ratio (M‐H, Random, 95% CI)	0.61 [0.35, 1.06]
5 total PE	12	12720	Risk Ratio (M‐H, Fixed, 95% CI)	1.24 [0.65, 2.34]
6 fatal PE	11	11477	Risk Ratio (M‐H, Fixed, 95% CI)	0.72 [0.25, 2.05]
7 non‐fatal PE	11	11486	Risk Ratio (M‐H, Fixed, 95% CI)	1.40 [0.63, 3.11]
8 major bleeding	13	12874	Risk Ratio (M‐H, Fixed, 95% CI)	1.34 [1.06, 1.68]
9 fatal bleeding	8	10499	Risk Ratio (M‐H, Fixed, 95% CI)	0.71 [0.14, 3.62]
10 all causes of death	12	12603	Risk Ratio (M‐H, Fixed, 95% CI)	0.88 [0.63, 1.22]
11 other serious adverse effects	11	12707	Risk Ratio (M‐H, Fixed, 95% CI)	1.06 [0.95, 1.20]